Results 311 to 320 of about 140,297 (347)
Some of the next articles are maybe not open access.
Current Opinion in Oncology, 2014
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
openaire +3 more sources
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
openaire +3 more sources
Antibody–Drug Conjugates in Uro-Oncology
Targeted Oncology, 2022Currently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment.
Dawid Sigorski +3 more
openaire +2 more sources
Biotechnology Letters, 2016
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
openaire +3 more sources
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
openaire +3 more sources
The Promise of Antibody–Drug Conjugates
New England Journal of Medicine, 2012The promise of antibody–drug conjugates (ADCs) is the specific targeting of highly potent cytotoxic agents to malignant disease without adversely affecting normal tissues. We may be on the verge of fulfilling that promise. This moment has been more than 25 years in the making and has required technology development in every facet of the conception and ...
James H. Doroshow, Beverly A. Teicher
openaire +3 more sources
Antibody–drug conjugates for cancer
The Lancet, 2019Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.
Patricia S. Steeg +2 more
openaire +2 more sources
Antibody–Drug Conjugates for Immunology
Journal of Medicinal Chemistry, 2022The application of antibody-drug conjugates (ADCs) to fields outside of oncology is increasing but is still relatively uncommon. A recent publication describes the conjugation of glucocorticoid receptor modulators to antibodies as a means of improving the separation between desired anti-inflammatory activity and unwanted systemic side effects.
openaire +2 more sources
Antibody–Drug Conjugates in Tumor Therapy
Pharmaceutical Patent Analyst, 2012Antibody-drug conjugates (ADCs) for tumor therapy contain a cytotoxic drug conjugated to a monoclonal antibody (mAb) across a linker. A homing device, the mAb enables the recognition of tumor cells by binding to tumor-specific antigens. The linker is usually cleaved inside the tumor cell or close to the cell surface according to a well-designed ...
Sammet, Benedikt +2 more
openaire +4 more sources
Antibody–Drug Conjugate Payloads
2013Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical
Torsten Hechler +3 more
openaire +3 more sources
Antibody–drug conjugates in lymphoma [PDF]
Clinical Investigation, 2014 Antibody–drug conjugates (ADCs) are comprised of monoclonal antibodies physically linked to cytotoxic molecules. They expressly target cancer cells by delivering cytotoxic agents to cells displaying specific antigens, and minimize damage to normal tissue.
Robert T. Chen, Nitya Nathwani
openaire +1 more source
Antibody-Drug Conjugate Targets
Current Cancer Drug Targets, 2009The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody-drug conjugates has been marked by hurdles identified and overcome. Early conjugates used
openaire +3 more sources